TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04581408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumacaftor / Ivacaftor, Orkambi® Oral Tablet
Description: Total daily dose: 800 mg of Lumacaftor and 500 mg of Ivacaftor.~Duration of treatment: according to the clinical conditions of the patient and based on the response to the drugs: up to a maximum of 7 days
Study: NCT05400044

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Three dimensional maxillary bone augmentation
Description: mixing of bone marrow aspirate concentrate with xenograft to show the bone quality and bone gain compared to the xenografts mixed with autografts

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Three dimensional maxillary bone augmentation
Description: mixing of bone marrow aspirate concentrate with xenograft to show the bone quality and bone gain compared to the xenografts mixed with autografts
Study: NCT05006456

Intervention type: DEVICE
Intervention: Catheter ablation
Description: Subjects will undergo catheter ablation using the new technologies, including THERMOCOOL SMARTTOUCH® SF catheter with Visitag SURPOINT, QDOT catheter and HELIOSTAR catheter when they are used in conjunction with Carto system for AF ablations.

Intervention type: DEVICE
Intervention: Catheter ablation
Description: Subjects will undergo catheter ablation using the new technologies, including THERMOCOOL SMARTTOUCH® SF catheter with Visitag SURPOINT, QDOT catheter and HELIOSTAR catheter when they are used in conjunction with Carto system for AF ablations.
Study: NCT05964153

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Liquid Biopsy
Description: Analysis of the circulating free DNA in blood patients affected by gliomas
Study: NCT05223803

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Prostate radiation (XRT)
Description: Both arms will receive prostate radiation. Multiple treatment regimens are allowed per protocol.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Prostate radiation (XRT)
Description: Both arms will receive prostate radiation. Multiple treatment regimens are allowed per protocol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systemic Therapy
Description: All systemic therapy is provided as best prescribed for patient per their medical oncologist.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systemic Therapy
Description: All systemic therapy is provided as best prescribed for patient per their medical oncologist.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic ablative radiation therapy (SABR)
Description: SABR is delivered to those randomized to Arm 2.
Study: NCT06783309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride for injection
Study: NCT05565820

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vamousse Spray 'n' Go
Description: Pediculicide for topical application, active ingredient Natrum Muriaticum 2X (HPUS).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nix Creme Rinse Lice Treatment
Description: 1% permethrin lotion for topical application.
Study: NCT06266988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril and Valsartan Tablets 97mg/103mg
Description: Each Tablet contains 97 mg of Sacubitril and 103 mg of Valsartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entresto (Sacubitril and Valsartan Tablets 97mg/103mg)
Description: Each Tablet contains 97.2 mg sacubitril and 102.8 mg valsartan as sodium salt complex
Study: NCT06783309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride for injection
Study: NCT06785207

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D-printed scoliosis brace
Description: Scoliosis brace will be 3D printed using a Filament Innovations Icarus printer and the material CPX. There will be corrugations where extra strength is needed. The brace will be made using the same shape as the participant's current brace to minimize variables at play.~According to Sec. 890.3490 of the Code of Federal Regulations Title 21, scoliosis braces are Class I devices, requiring only general controls. This device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 890.9. The device is also exempt from the current good manufacturing practice requirements of the quality system regulation in part 820 of this chapter, with the exception of § 820.180, regarding general requirements concerning records and § 820.198, regarding complaint files.
Study: NCT06786078

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lily Device
Description: Participants will wear the Lily Device at each chemotherapy session for the prescribed duration, where the device must be used during infusion and for at least two (2) hours and up to four (4) hours post infusion.
Study: NCT06783478

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK cell infusion
Description: Six infusions of 1 x 10⁷/kg of haploidentical NK cells, in vitro expanded and activated.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Six infusions of placebo
Study: NCT06782893

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-pharmacological cough control therapy
Description: Over seven weeks (1 session per week, except session 5, which will be 2 weeks after session 4) using a one-on-one hybrid model. In session 1, participants will receive general education about chronic cough, introduction to cough suppression and goal setting. Session 2 will cover education about chronic cough in ILD, cough triggers and training in cough suppression techniques. Session 3 will focus on hydration techniques, laryngeal hygiene, and breathing exercises to control coughing. Session 4 will reinforce all aspects of non-pharmacological cough control treatment, and session 5 will explore the sustainability of cough control strategies after the program using real-life case scenarios.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Healthy lifestyle
Description: Over seven weeks (1 session per week, except session 5, which will be 2 weeks after session 4) using a one-on-one hybrid model. In session 1, participants will receive general education about exercise and physical activity. Session 2 will cover education about diet. Session 3 will focus on stress management. Session 4 will cover relaxation techniques, and session 5 will reinforce all aspects previously considered.
Study: NCT06782061

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DSM17938+Routine clinical treatment
Description: Lactobacillus reuteri DSM17938，5 drops per day by mouth (containing at least 100 million CFU of Lactobacillus reuteri DSM17938)，Routine clinical treatment
Study: NCT06783361

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation with figure-eight coil
Description: A total of 50 sessions will be applied for 2 weeks, 5 sessions a day, 5 days a week. There will be at least 30 minutes rest time between each session. It includes first an intermittent theta burst (iTBS) protocol at a frequency of 5 Hz with 1800 pulses to the left DLPFC at 90% motor threshold, followed by a continuous theta burst (cTBS) protocol at a frequency of 5 Hz with 600 pulses to the right DLPFC at 80% motor threshold.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation with figure-eight coil
Description: A total of 50 sessions will be applied for 2 weeks, 5 sessions a day, 5 days a week. There will be at least 30 minutes rest time between each session. One session will consist of a high frequency (5 Hz) intermittent theta burst (iTBS) of 1800 pulses at 90% motor threshold to the left DLPFC followed by a pseudo continuous theta burst (cTBS) of 600 pulses at 5 Hz frequency at 80% motor threshold to the right DLPFC. The sham cTBS treatment will be applied by placing the coil at a 45-degree angle to the application site.
Study: NCT06784583

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous auricular vagus nerve stimulation
Description: 1. Prior to execution: Remove jewelry (such as earrings) that may interfere with the electrode placement; attach the electrodes to the tragus of the left ear; feed the wires over the right shoulder from the back of the neck, and then turn on the device.~2. Initiate stimulation: Establish the following parameters: 200 μs pulse width, 30 Hz frequency, 0-36 mA current intensity (modify to the most appropriate stimulation intensity based on the patient's pain perception), and one-hour timing. Next, begin the stimulation.~3. Stimulation end: After an hour, the device will be automatically switched off. And the procedure is finished.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham transcutaneous auricular vagus nerve stimulation
Description: 1. Prior to execution: Remove jewelry (such as earrings) that may interfere with the electrode placement; attach the electrodes to the tragus of the left ear; feed the wires over the right shoulder from the back of the neck, and then turn on the device.~2. Initiate stimulation: Establish the following parameters: 200 μs pulse width, 30 Hz frequency, 0-36 mA current intensity (modify to the most appropriate stimulation intensity based on the patient's pain perception). Next, turn off the stimulation，and one-hour timing.~3. Stimulation end: After an hour, the device will be removed and the procedure is finished.
Study: NCT06045234

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urine sampling
Description: Among the 300 people recruited:~* 300 will each provide 3 urine samples collected on 3 different days during a week (e.g. Monday, Wednesday and Friday)~* 50 will each provide 3 urine samples collected at sunrise, in the middle and then at the end of the day over a period of 24 hours, on 3 different days during a week (e.g. Monday, Wednesday and Friday).
Study: NCT06782945

Intervention type: DIETARY_SUPPLEMENT
Intervention: BIOHM FX Probiotic Blend
Description: BIOHM Health has been selling BIOHM FX, a blend of probiotics as a dietary supplement addressed at the digestive health market since 2017. The blend is present in the market in various concentrations ranging from 30 Billion CFU to 1 Billion CFU. The probiotic blend consists of Lactobacillus acidophilus, Lactobacillus rhamnosus, Saccharomyces boulardii, Bifidobacterium breve and amylase. The blend is manufactured at cGMP facilities located in the United States and has attained self GRAS status. Prior to release, each lot of probiotic blend is tested for heavy metals, objectionable organisms, water content, probiotic potency, enzyme activity level and allergens, Soy, Milk and Gluten. Additionally, BIOHM performs annual testing for a full FALCPA panel of allergens ensuring there are no allergens present in the blend.

Intervention type: DIETARY_SUPPLEMENT
Intervention: BIOHM FX Probiotic Blend
Description: BIOHM Health has been selling BIOHM FX, a blend of probiotics as a dietary supplement addressed at the digestive health market since 2017. The blend is present in the market in various concentrations ranging from 30 Billion CFU to 1 Billion CFU. The probiotic blend consists of Lactobacillus acidophilus, Lactobacillus rhamnosus, Saccharomyces boulardii, Bifidobacterium breve and amylase. The blend is manufactured at cGMP facilities located in the United States and has attained self GRAS status. Prior to release, each lot of probiotic blend is tested for heavy metals, objectionable organisms, water content, probiotic potency, enzyme activity level and allergens, Soy, Milk and Gluten. Additionally, BIOHM performs annual testing for a full FALCPA panel of allergens ensuring there are no allergens present in the blend.

Intervention type: DIETARY_SUPPLEMENT
Intervention: BIOHM FX Probiotic Blend
Description: BIOHM Health has been selling BIOHM FX, a blend of probiotics as a dietary supplement addressed at the digestive health market since 2017. The blend is present in the market in various concentrations ranging from 30 Billion CFU to 1 Billion CFU. The probiotic blend consists of Lactobacillus acidophilus, Lactobacillus rhamnosus, Saccharomyces boulardii, Bifidobacterium breve and amylase. The blend is manufactured at cGMP facilities located in the United States and has attained self GRAS status. Prior to release, each lot of probiotic blend is tested for heavy metals, objectionable organisms, water content, probiotic potency, enzyme activity level and allergens, Soy, Milk and Gluten. Additionally, BIOHM performs annual testing for a full FALCPA panel of allergens ensuring there are no allergens present in the blend.
Study: NCT06784245

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Synchronous telerehabilitation program
Description: About physiotherapy telerehabilitation sessions, few investigators have conducted well-designed investigations into whether patients achieve comparable benefit from in-clinic and remote physiotherapy services. Much of the research that exists implements a hybrid model of combined home and clinic sessions rather than just remote delivery (42). In this context, this study has been designed as a blinded (assessor and statistician), parallel group, randomized controlled trial (RCT) that aims to analyze the effectiveness of synchronous telerehabilitation on the physical condition, functional status, and quality of life of older people considers the disadvantages suggested by the literature and generates proposals in the study methodology to counteract them.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Synchronous telerehabilitation program
Description: About physiotherapy telerehabilitation sessions, few investigators have conducted well-designed investigations into whether patients achieve comparable benefit from in-clinic and remote physiotherapy services. Much of the research that exists implements a hybrid model of combined home and clinic sessions rather than just remote delivery (42). In this context, this study has been designed as a blinded (assessor and statistician), parallel group, randomized controlled trial (RCT) that aims to analyze the effectiveness of synchronous telerehabilitation on the physical condition, functional status, and quality of life of older people considers the disadvantages suggested by the literature and generates proposals in the study methodology to counteract them.
Study: NCT05400980

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Urocross implant
Description: Urocross implant inserted via delivery catheter

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Sham-control
Description: Cystoscopy
Study: NCT06294158

Intervention type: OTHER
Intervention: Brightness measurement
Description: Measurement of ambience brightness using lux meters

Intervention type: OTHER
Intervention: Sound level measurement
Description: Measurement of ambience sound levels using sound level meters
Study: NCT05205811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Extended-release bupropion dosing (150 mg each morning days 1-3, then 300 mg/daily) for the remainder of the 7 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Extended-release bupropion dosing (150 mg each morning days 1-3, then 300 mg/daily) for the remainder of the 7 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide
Description: Zonisamide (100 mg/daily) for 7 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo bupropion
Description: Placebo bupropion for 7 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo zonisamide
Description: Placebo zonisamide for 7 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo zonisamide
Description: Placebo zonisamide for 7 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-cigarette
Description: e-cigarette for ad libitum use for two weeks prior to complete switch day and for an additional 10 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-cigarette
Description: e-cigarette for ad libitum use for two weeks prior to complete switch day and for an additional 10 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: E-cigarette
Description: e-cigarette for ad libitum use for two weeks prior to complete switch day and for an additional 10 weeks.
Study: NCT04840589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BET Bromodomain Inhibitor ZEN-3694
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BET Bromodomain Inhibitor ZEN-3694
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo a biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo a biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo a CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo a CT scan

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT05296915

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tVNS
Description: An electric current with a frequency of 25 Hz (Figure 2) will be applied to the cymba conca of the left ear through a specific device (VITOS, Cerbomed, Germany; CE marking). The stimulation intensity will be customized between 0.1 and 5 mA according to the sensitivity threshold of each participant. Patients will be instructed to perform tVNS at home for 4 non-consecutive hours per day for 12 weeks, in accordance with the protocol reported in the literature for the treatment of major depression.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: The stimulation will be carried out with a TMS STM9000 system (Ates, Medica Device s.r.l., Italy) equipped with a 70 mm butterfly cooled coil. The stimulation protocol followed will be the one approved by the FDA for major depression, that is, a stimulation at the level of the left dorsolateral prefrontal cortex at an intensity equal to 120% of the motor threshold, at the frequency of 10hz. Each stimulation session will last 37.5 minutes, and will consist of 75 trains lasting 4 seconds, with a 26-second break between each train. During each session, a total of 3000 stimuli will be administered. The sessions will take place 5 days a week, from Monday to Friday, for 4 weeks, and for a total of 20 sessions of stimulation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-E
Description: Targeted cognitive-behavioral therapy following the CBT-E protocol (CG Fairburn - 2010. La terapia cognitivo-comportamentale dei disturbi dell'alimentazione. Firenze, Eclipsi; 2010.)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-E
Description: Targeted cognitive-behavioral therapy following the CBT-E protocol (CG Fairburn - 2010. La terapia cognitivo-comportamentale dei disturbi dell'alimentazione. Firenze, Eclipsi; 2010.)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-E
Description: Targeted cognitive-behavioral therapy following the CBT-E protocol (CG Fairburn - 2010. La terapia cognitivo-comportamentale dei disturbi dell'alimentazione. Firenze, Eclipsi; 2010.)
Study: NCT04840589

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT06232083

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PLDR+Cardunizumab
Description: Application of PLDR external irradiation combined with Cardunizumab in recurrent cervical cancer
Study: NCT05501691

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Laser Simulation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 445 nm Diode Laser Wavelength
Description: The Axial Surface of Class V Cavity will be Irradiated Using a 445 nm Diode Laser Wavelength

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 660 nm Diode Laser Wavelength
Description: The Axial Surface of Class V Cavity will be Irradiated Using a 660 nm Diode Laser Wavelength

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 970 nm Diode Laser Wavelength
Description: The Axial Surface of Class V Cavity will be Irradiated Using a 970 nm Diode Laser Wavelength
Study: NCT05327166

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ED-LINC
Description: The ED-LINC intervention provides 1) overdose education, 2) brief bedside intervention targeting motivation to engage in outpatient care, 3) a patient-centered approach to MOUD using a treatment decision support tool, 4) longitudinal and proactive care management which will proceed for 3 months, and 5) weekly caseload supervision allowing for stepped-up care targeting opioid use and comorbidity.
Study: NCT06464328

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi Combined with Music Therapy Intervention
Description: Tai Chi combined with music therapy Intervention, the effect was achieved by replacing the school's physical education classes with Tai Chi of the researchers' choice, and then by playing music of the researchers' choice during class; twice a week for twelve weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music intervention only
Description: Music only (120-130 bpm) The effect was achieved by playing music selected by the researchers during originally physical education classes in school; twice a week for twelve weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi intervention only
Description: Tai Chi intervention only The effect was achieved by replacing the school's originally physical education classes with Tai Chi of the researchers' choice; twice a week for twelve weeks